• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Commercial Insurance Coverage Criteria for Autologous Chondrocyte Implantation Poorly Reflect Current Research.自体软骨细胞移植的商业保险覆盖标准未能充分反映当前研究成果。
Cartilage. 2024 Sep 30:19476035241276930. doi: 10.1177/19476035241276930.
2
The Literature that Commercial Insurance Payers Use to Substantiate Knee Osteochondral Allograft Policies Are of a Low Level of Evidence.商业保险支付方用于证实膝关节异体骨软骨移植政策的文献证据水平较低。
Cartilage. 2024 Aug 30:19476035241276859. doi: 10.1177/19476035241276859.
3
Commercial Insurance Payer Coverage Criteria for Meniscal Allograft Transplantation Poorly Reflect Modern Indications for the Procedure.半月板同种异体移植的商业保险支付方覆盖标准难以反映该手术的现代适应症。
Cartilage. 2025 Mar 28:19476035251329223. doi: 10.1177/19476035251329223.
4
Clinical and cost-effectiveness of autologous chondrocyte implantation for cartilage defects in knee joints: systematic review and economic evaluation.自体软骨细胞植入治疗膝关节软骨缺损的临床疗效与成本效益:系统评价与经济学评估
Health Technol Assess. 2005 Dec;9(47):iii-iv, ix-x, 1-82. doi: 10.3310/hta9470.
5
Clinical guidelines and payer policies on fusion for the treatment of chronic low back pain.临床指南和支付方政策对慢性下腰痛融合治疗的影响。
Spine (Phila Pa 1976). 2011 Oct 1;36(21 Suppl):S144-63. doi: 10.1097/BRS.0b013e31822ef5b4.
6
Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis.成人伴或不伴有广场恐惧症的惊恐障碍的心理治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2016 Apr 13;4(4):CD011004. doi: 10.1002/14651858.CD011004.pub2.
7
Surveillance for Violent Deaths - National Violent Death Reporting System, 50 States, the District of Columbia, and Puerto Rico, 2022.暴力死亡监测——2022年全国暴力死亡报告系统,50个州、哥伦比亚特区和波多黎各
MMWR Surveill Summ. 2025 Jun 12;74(5):1-42. doi: 10.15585/mmwr.ss7405a1.
8
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
9
Evidence-based status of second- and third-generation autologous chondrocyte implantation over first generation: a systematic review of level I and II studies.基于证据的第二代和第三代自体软骨细胞移植与第一代相比的地位:I 级和 II 级研究的系统评价。
Arthroscopy. 2013 Nov;29(11):1872-8. doi: 10.1016/j.arthro.2013.07.271. Epub 2013 Sep 26.
10
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.戈谢病酶替代疗法的临床疗效和成本效益:一项系统评价。
Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. doi: 10.3310/hta10240.

本文引用的文献

1
Poor evidence is used to support commercial payers' coverage policies for shoulder arthroplasty.证据不足却被用于支持商业医保机构关于肩关节置换术的保险政策。
J Shoulder Elbow Surg. 2023 Nov;32(11):2222-2231. doi: 10.1016/j.jse.2023.04.014. Epub 2023 May 27.
2
A Randomized Trial of Autologous Chondrocyte Implantation Versus Alternative Forms of Surgical Cartilage Management in Patients With a Failed Primary Treatment for Chondral or Osteochondral Defects in the Knee.自体软骨细胞移植与其他形式的手术软骨管理治疗膝关节初次治疗失败的软骨或骨软骨缺损患者的随机对照试验。
Am J Sports Med. 2023 Feb;51(2):367-378. doi: 10.1177/03635465221141907. Epub 2023 Jan 20.
3
Sustained superiority in KOOS subscores after matrix-associated chondrocyte implantation using spheroids compared to microfracture.与微骨折相比,使用球体的基质相关软骨细胞植入后 KOOS 亚评分持续优越。
Knee Surg Sports Traumatol Arthrosc. 2023 Jun;31(6):2482-2493. doi: 10.1007/s00167-022-07194-x. Epub 2022 Oct 21.
4
Global Variation in Studies of Articular Cartilage Procedures of the Knee: A Systematic Review.全球膝关节软骨关节镜手术研究的差异:系统评价。
Cartilage. 2022 Apr-Jun;13(2):19476035221098169. doi: 10.1177/19476035221098169.
5
Third-Generation Autologous Chondrocyte Implantation (Cells Cultured Within Collagen Membrane) Is Superior to Microfracture for Focal Chondral Defects of the Knee Joint: Systematic Review and Meta-analysis.第三代自体软骨细胞移植(胶原膜内培养的细胞)优于微骨折治疗膝关节局灶性软骨缺损:系统评价和荟萃分析。
Arthroscopy. 2022 Aug;38(8):2579-2586. doi: 10.1016/j.arthro.2022.02.011. Epub 2022 Mar 10.
6
Time Matters: Knee Cartilage Defect Expansion and High-Grade Lesion Formation while Awaiting Autologous Chondrocyte Implantation.时间就是生命:等待自体软骨细胞移植时,软骨缺陷的扩大和高级别病变的形成。
Cartilage. 2021 Dec;13(2_suppl):1802S-1808S. doi: 10.1177/19476035211063866. Epub 2021 Dec 11.
7
Injectable autologous chondrocyte implantation in acetabular cartilage defects: 2-year minimum clinical and MRI results.髋关节软骨缺损的可注射自体软骨细胞移植:2 年最低临床和 MRI 结果。
Arch Orthop Trauma Surg. 2023 Feb;143(2):739-747. doi: 10.1007/s00402-021-04141-2. Epub 2021 Sep 1.
8
What is the Level of Evidence Substantiating Commercial Payers' Coverage Policies for Total Joint Arthroplasty?有哪些证据可以证明商业保险公司的全关节置换术覆盖政策?
J Arthroplasty. 2021 Aug;36(8):2665-2673.e8. doi: 10.1016/j.arth.2021.03.036. Epub 2021 Mar 22.
9
Prospective Long-term Follow-up of Autologous Chondrocyte Implantation With Periosteum Versus Matrix-Associated Autologous Chondrocyte Implantation: A Randomized Clinical Trial.前瞻性自体软骨细胞植入与骨膜-细胞外基质复合物自体软骨细胞植入的长期随访:一项随机临床试验。
Am J Sports Med. 2020 Jul;48(9):2230-2241. doi: 10.1177/0363546520928337.
10
Trends in the Surgical Treatment of Articular Cartilage Lesions in the United States from 2007 to 2016.2007年至2016年美国关节软骨损伤外科治疗的趋势
J Knee Surg. 2021 Dec;34(14):1609-1616. doi: 10.1055/s-0040-1712946. Epub 2020 May 29.

自体软骨细胞移植的商业保险覆盖标准未能充分反映当前研究成果。

Commercial Insurance Coverage Criteria for Autologous Chondrocyte Implantation Poorly Reflect Current Research.

作者信息

Kotlier Jacob L, Lin Eric H, Fathi Amir, Iyer Avinash S, Telang Sahil S, Bolia Ioanna K, Ahmad Aamir, Petrigliano Frank A, Liu Joseph N

机构信息

Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA.

出版信息

Cartilage. 2024 Sep 30:19476035241276930. doi: 10.1177/19476035241276930.

DOI:10.1177/19476035241276930
PMID:39345049
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11556559/
Abstract

OBJECTIVE

The aim of this study is to both quantify and qualify the way insurance companies justify their coverage policies for autologous chondrocyte implantation (ACI) and determine whether these policies align with recent research on the subject.

DESIGN

The top 11 national commercial health insurance payers for ACI were identified. Coverage policy documents were recovered for 8 payers. These documents were examined, and the type of reference and the level of evidence (LOE) were recorded for each applicable reference. Specific coverage criteria for each individual payer were then extracted and assessed for similarities among commercial payers. Finally, all references cited by each payer were examined to determine whether they mentioned the specific payer criteria.

RESULTS

This study found that the majority of cited references were primary journal articles (86, 58.1%) and that only 30 (20.2%) references were level I or level II evidence. This study also found significant homogeneity among payer coverage criteria. Cited sources inconsistently mentioned specific payer coverage criteria. In addition, payer criteria tended to be poorly supported by current evidence on ACI.

CONCLUSIONS

This study demonstrates that commercial insurance payers' coverage policies for ACI poorly cite references, cite a majority of references with low LOE, and cite references which infrequently mention their specific coverage criteria. In addition, payer coverage policies have a high degree of homogeneity and many of their specific criteria are poorly supported by current research on ACI.

摘要

目的

本研究旨在量化并定性保险公司为自体软骨细胞植入术(ACI)制定保险覆盖政策的方式,并确定这些政策是否与该主题的最新研究一致。

设计

确定了11家为ACI提供保险的全国性商业健康保险公司。获取了其中8家保险公司的保险覆盖政策文件。对这些文件进行审查,并记录每个适用参考文献的参考文献类型和证据水平(LOE)。然后提取每个保险公司的具体保险覆盖标准,并评估商业保险公司之间的相似性。最后,审查每个保险公司引用的所有参考文献,以确定它们是否提及了具体的保险公司标准。

结果

本研究发现,大多数引用的参考文献是初级期刊文章(86篇,58.1%),只有30篇(20.2%)参考文献为I级或II级证据。本研究还发现保险公司的保险覆盖标准之间存在显著的同质性。引用的资料来源不一致地提及具体的保险公司保险覆盖标准。此外,目前关于ACI的证据对保险公司标准的支持往往不足。

结论

本研究表明,商业保险公司对ACI的保险覆盖政策参考文献引用不佳,大多数引用的参考文献证据水平较低,且引用的参考文献很少提及它们的具体保险覆盖标准。此外,保险公司的保险覆盖政策具有高度同质性,其许多具体标准在目前关于ACI的研究中支持不足。